GTGustav Torisson

Gustav Torisson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gustav Torisson has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Blood culture time to positivity corrected for delayed incubation start - a population-based study

    by Karl Oldberg, Torgny Sunnerhagen, Oskar Ljungquist, Magnus Rasmussen, Jonas Tverring, Gustav Torisson

    Purpose: A short blood culture time to positivity (TTP) is associated with an increased risk for death in blood stream infections (BSI). However, TTP is also shortened when the time elapsed from sampling to incubation start (TTI) increases. We aimed to test whether TTP corrected for TTI was more strongly associated with 7-day mortality in BSI. Methods: This was a retrospective analysis of positive blood culture bottles in Skåne region, Sweden, 2015 to 2023, with linked clinical data obtained from healthcare databases. Correction factors were derived using linear regression between TTI and TTP. The association between TTP and 7-day mortality was studied in BSI episodes, using non-linear logistic regression. Actual mortality rates and odds ratios (OR) for different TTP cutoffs were calculated. Results: In total, 100,829 bottles were included and each hour of TTI was associated with a shortening of TTP by 0.27 h in aerobic bottles and 0.32 h in anaerobic bottles. After deduplication, 31,723 unique BSI episodes were included in mortality analysis, with a 7-day mortality rate of 6.4%. In non-linear regression models, corrected TTP showed a stronger association with 7-day mortality than crude TTP in episodes with TTP < 10 h. Actual mortality rates were higher for corrected TTP at all cutoffs between 6 and 12 h. Conclusion: TTP corrected for TTI was more strongly associated with 7-day mortality than crude TTP. We recommend that correction for TTI should be used in future studies on TTP, especially if on-site incubation is unavailable.

  • Open Access

    Etiology and Outcomes of Bloodstream Infections by Immunosuppression Type: A Population-Based Laboratory Surveillance Study

    by Oskar Ljungquist, Fredrik Resman, Karl Oldberg, Anna Bläckberg, Torgny Sunnerhagen, Gustav Torisson

    Background: An increasing proportion of the population receives immunosuppressive treatment. There is a lack of guidelines for bloodstream infections (BSIs) in this group. This study aims to provide a comprehensive analysis of the etiology and outcomes in BSI associated with underlying immunosuppression. Methods: This population-based laboratory surveillance study included all positive blood cultures in southern Sweden, from 2013 through 2023. Immunosuppression was defined using diagnostic codes, medications, and laboratory data. We defined 6 categories of immunosuppression: antineoplastic treatment, neutropenia, immunosuppressant medication, organ transplants, primary immunodeficiency, and human immunodeficiency virus infection. Results: In total, 8058 of 47 552 (16.9%) BSI episodes were associated with underlying immunosuppression. This proportion increased over time (rate ratio, 1.019 per year [95% confidence interval {CI}, 1.012–1.027], P < .001). Immunosuppression was associated with a higher degree of Enterococcus faecium (odds ratio [OR], 3.16 [95% CI, 2.63–3.78]) and Pseudomonas spp (OR, 2.51 [95% CI, 2.16–2.91]) etiology. Intrinsic cephalosporin resistance was more frequent in BSI episodes with underlying immunosuppression (OR, 1.45 [95% CI, 1.36–1.55]). The 30-day mortality rate was higher in BSI episodes with underlying immunosuppression, at 17.9% (1439/8044), compared to 12.5% (4880/39 089) in episodes without immunosuppression (OR, 1.54 [95% CI, 1.45–1.64]). Conclusions: This study provides an updated summary of etiology and outcomes in BSI associated with immunosuppression. Underlying immunosuppression is increasingly prevalent among patients with BSI and is associated with resistance to cephalosporins and increased short-term mortality. Clinical guidelines for the management of BSI in immunosuppressed patients are warranted.

  • Open Access

    Intravenous Immunoglobulin Treatment in Patients With Streptococcal Toxic Shock Syndrome in Southern Sweden: A Retrospective Population-Based Study

    by Olof Wullt, Charlotta Utbult, Erik Carlson, Oskar Ljungquist, Torgny Sunnerhagen, Anna Bläckberg, Gustav Torisson

    Background: Intravenous immunoglobulins (IVIGs) have been suggested as an adjunctive treatment in streptococcal toxic shock syndrome (STSS), but there are no conclusive trials. In southern Sweden, IVIG is routinely used in certain hospitals but not others. We hypothesized that this would resemble a natural experiment, and we aimed to evaluate the effect of IVIG in patients with STSS. Method: We conducted a population-based retrospective cohort study on STSS cases in southern Sweden from 2017 to 2024. The main exposure was any IVIG treatment, and the primary outcome was 30-day mortality. Cox regression was used, adjusted for lactate, Sequential Organ Failure Assessment score, Charlson Comorbidity Index, and concurrent clindamycin treatment. We modeled IVIG as a time-dependent variable to address immortal time bias. Results: In total, 106 patients fulfilled STSS criteria, of which 56 (53%) were treated with IVIG. Despite geographic differences, the IVIG group was younger and had fewer comorbidities but higher disease severity at baseline. Crude analysis suggested lower mortality in the IVIG group (hazard ratio, 0.69; 95% CI, .34–1.41). However, after adjusting for covariates and accounting for immortal time bias, the hazard ratio was estimated at 1.69 (95% CI, .66–4.30). Conclusions: Although our study included a large population of patients with STSS, our results were inconclusive regarding the effect of IVIG on 30-day mortality. This study highlights the risk of bias in observational studies in rare conditions. Prospective interventional studies are needed to determine the efficacy of IVIG in patients with STSS.

  • Open Access

    Determinants of empiric combination antibiotic therapy for hospital associated bloodstream infections in the intensive care unit

    by Evaldas Kauzonas, Gustav Torisson, Juan Merlo, Raquel Perez, Alexis Tabah, Niccolò Buetti, Stéphane Ruckly, François Barbier, Jean-François Timsit, Fredrik Sjövall

    Empiric combination antibiotic therapy (ECAT) is commonly used to treat healthcare-associated bloodstream infections (HA-BSIs) and sepsis. However, the level of supporting evidence is low and clinical practice varies significantly. We conducted a post hoc analysis using the EUROBACT-2 international cohort study database, which contained data on 2406 adult patients from 328 intensive care units (ICUs) across 52 countries, collected between June 2019 and January 2021. The main outcome was the proportion of patients receiving ECAT for HA-BSIs. Patient and institutional factors influencing the use of ECAT were examined using Markov-Chain Monte Carlo estimation. Three quarters of patients (75.2%; n = 1810) received empiric antibiotic therapy, with ECAT used in approximately half of cases (52.5%; n = 950). Most patients receiving ECAT (70.4%; n = 669) were treated with two antibiotics, beta-lactams plus glycopeptides being the most common combination (40.2%; n = 382). The odds of ECAT were increased by immune deficiency (OR 1.35 [95% CrI 1.03–1.75]), SOFA scores > 11 (OR 1.77 [95% CrI 1.28–2.46]), uncommon sources of infection (OR 1.63 [95% CrI 1.02–2.59]), and admission to ICUs where > 25% of Enterobacteriaceae isolates produce carbapenemases (OR 2.46 [95% CrI 1.37–4.41). The intra-class correlation coefficients at the ICU and country levels were 23.2% and 4.4%, respectively. In conclusion, factors at the individual, institutional, and national levels may affect the use of ECAT to treat HA-BSIs. Given the impact of institutional variables on the use of ECAT and the inconclusive evidence regarding its potential risks, it is of great importance that treatment is tailored based on local antibiotic stewardship programs and the needs of the individual patient.


  • Open Access

    Association of time to positivity with disease severity in bloodstream infections—a population-based cohort study

    by Oskar Ljungquist, Jonas Tverring, Karl Oldberg, Torgny Sunnerhagen, Gustav Torisson


  • Open Access

    Treating shock with norepinephrine administered in midline catheters in an intermediary care unit: a retrospective cohort study

    by Hanna Karlsson, Ajnaz Afrasiabi, Marcus Ohlsson, Viktor Månsson, Hannes Hartman, Gustav Torisson

    Objectives A rising incidence of septic shock as well as recommendations for early vasopressor initiation has increased the number of patients eligible for norepinephrine (NE). Traditionally, NE has been administered through central lines, in intensive care units, due to the risk of extravasation in peripheral lines. The aim of the current study is to determine the rate of complications and patient outcomes when NE is administered through midline catheters (MCs) in intermediary care units (IMCUs). Design Retrospective cohort study. Setting Three IMCUs in southern Sweden Participants Patients with septic shock who received NE through a MC from September 2020 through March 2023. Primary and secondary outcome measures The primary outcome was a major complication to treatment, defined as extravasation of NE, catheter-associated venous thromboembolism and catheter-associated bloodstream infection (BSI). Secondary outcomes included patient outcomes after intermediary care (either deceased, discharged to regular ward care or intensive care) and the need for additional central lines. Results Of 474 eligible patients, 472 were included, with a median (IQR) age of 73.5 (65–80) years, with 281 (60%) men. The median (IQR) duration of NE infusion was 21 (9–38) hours, with a median (IQR) dosage of 0.12 (0.08–0.20) µg/kg/min. Major complications occurred in 12 cases (2.5%), with one suspected extravasation, seven thromboembolic events and four catheter-related BSIs. After intermediary care, 334 patients (71%) were discharged to regular ward care, 66 patients (14%) were escalated to intensive care and 72 (15%) died in intermediary care, of whom 69 had a documented ceiling of care decision. 100 patients (21%) received a central line. Conclusion NE administration in MCs was associated with a low rate of short-term complications and could decrease the need for central lines. MCs can enable the initial management of circulatory failure outside intensive care, but more studies are needed to determine the long-term value of IMCUs. Trial registration number NCT06121115.


  • Clinical outcomes in combination versus mono antibiotic therapy in ICU admitted patients with a suspected infection - A substudy of the DIANA study

    by Nima Tanha, Ilja Areskog Lejbman, Liesbet De Bus, Gennaro De Pascale, José Garnacho-Montero, Marc Leone, Shigeki Fujitan, Jan J. De Waele, Gustav Torisson, Fredrik Sjövall


  • Open Access

    Agreement and reliability of hepatic transient elastography in patients with chronic hepatitis C: A cross‐sectional test–retest study

    by Oskar Ljungquist, Jon Olinder, Jonas Tverring, Charlott Kjölvmark, Gustav Torisson

    Background and Aims: Transient elastography (TE) has largely replaced liver biopsy to evaluate fibrosis stage and cirrhosis in chronic hepatitis C. Previous studies have reported excellent reliability of TE but agreement metrics have not been reported. This study aimed to assess interrater agreement and reliability of repeated TE measurements.Methods: Two operators performed TE independently, directly after each other. The primary outcome was disagreement, defined as a difference in TE results between operators of ≥33%, as well as the smallest detectable change, SDC95 (i.e., the difference between measurements needed to state with 95% certainty that there is a difference in underlying stiffness). Secondary outcomes included reliability, measured as intraclass correlation (ICC), and patient and examination characteristics associated with the agreement.Results: In total, 65 patients were included, with a mean liver stiffness of 9.7 kPa. Of these, 21 (32%) had a disagreement in TE results of ≥33% between the two operators. The SDC95 on the log scale was 1.97, indicating that an almost twofold increase or decrease in liver stiffness would be required to confidently represent a change in the underlying fibrosis. Reliability, estimated using the ICC, was acceptable at 0.86. In a post hoc analysis, fasting less than 5 h before TE was associated with a higher degree of disagreement (48% vs. 19%, p = 0.03).Conclusions: In our clinical setting, interrater agreement in directly repeated TE measurements was surprisingly low. It is essential to further investigate the reliability and agreement of TE to determine its validity and usefulness.


  • Open Access

    Increasing rates of urinary and bloodstream infections following transrectal prostate biopsy in South Sweden

    by Oskar Ljungquist, Ale Persmark, Magnus Grabe, Ane Krag Jakobsen, Axel Gerdtsson, Gustav Torisson, Anders Bjartell, Kristian Riesbeck